Please login to the form below
gram-negative bacteria
This page shows the latest gram-negative bacteria news and features for those working in and with pharma, biotech and healthcare.
Pfizer’s antibiotic combination shows promise in treating multi-drug resistant infections
negative bacteria. ... plus metronidazole treatment arm who had infections due to confirmed MBL-producing gram-negative bacteria were cured, versus 0% of those on best available therapy.
Latest news
-
New research shows drug candidate may effectively treat antibiotic-resistant bacteria
Fabimycin demonstrated the potential to infiltrate the defences of gram-negative bacteria and treat infections, while leaving other helpful microbes intact. ... Gram-negative bacteria are a class of microbes that infect millions of people worldwide,
-
UK selects Shionogi’s Fetcroja for antimicrobial reimbursement scheme
The antibiotic treats infections caused by aerobic Gram-negative bacteria. Shionogi’s novel antibiotic Fetcroja has been selected for inclusion in a pilot subscription reimbursement scheme, launched by the UK’s ... Fetcroja was launched in the UK in
-
MSD launches antibiotic combo Recarbrio in UK
Therapeutic indicated to treat infections caused by Gram-negative bacteria. MSD (also known as Merck &Co) has launched its novel antibiotic combination Recarbrio in the UK. ... In a pivotal phase 3 trial of adult patients with infections caused by
-
Shionogi’s novel antibiotic trial data published in The Lancet
The APEKS-NP study evaluated Fetcroja in severely ill patients with hospital-acquired, ventilator-associated or healthcare-associated pneumonia caused by a broad range of Gram-negative bacteria. ... Fetcroja launched in the UK in September, launching as
-
Shionogi's Gram-negative antibiotic launches in the UK
aerobic Gram-negative bacteria in adults. ... all Gram-negative pathogens considered to be of 'critical priority' by the World Health Organization.
More from news
Approximately 0 fully matching, plus 21 partially matching documents found.
Latest Intelligence
-
Deal Watch January 2016
using Warp's SMART and genome mining platforms for the discovery of oncology therapeutics and antibiotics targeting Gram negative bacteria.
-
Deal Watch table for February 2014
270. Discuva / Roche. Collaboration. Antibiotics to target multi-drug resistant Gram negative bacteria.
-
Pharma deals during February 2014
BATON studies in colorectal cancer and metastatic triple negative breast cancer. ... In the meantime, Roche's pRED group will make use of Discuva's development technology, which uses gene sequencing and bioinformatics to identify targets for multi-drug
-
Pharma deals during March 2013
This combined intravenous therapy is currently undergoing phase III clinical trials as a potential first-line treatment for complicated intra-abdominal and urinary tract infections caused by certain Gram-negative bacteria, ... Astellas Pharma/ Cubist
More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.
Subscribe to our email news alerts
- Account Manager, Healthcare Marketing Creative Agency, Fixed ter...
- Highly competitive salary
- Market Access Director, six figure base salary and £5K joining b...
- Highly competitive salary
- Senior Medical Copywriter - Highly Awarded Advertising Agency
- £50,000 - £60,000 yearly
- Home Based Account Manager, Medical Communications, UK, Pharma/M...
- Highly competitive salary
- Account Director, Healthcare Marketing Creative Agency, Fixed te...
- Highly competitive salary
- Account Manager, 6 month contract, Healthcare Brand communicatio...
- Highly competitive salary
- Novartis receives EC approval for Cosentyx in hidradenitis suppurativa
- BMS and Janssen’s antithrombotic granted FDA fast track designation
- Sanofi's frexalimab shows promise in relapsing forms of MS
- Amgen reports positive results for Otezla in psoriatic arthritis
- EMA recommends revoking marketing authorisation for Novartis’ sickle cell disease drug
- Seqera Labs and Genomics England partner to progress genomic research
- Pfizer’s antibiotic combination shows promise in treating multi-drug resistant infections
- Supporting the most vulnerable: why pharma should get behind the NHS’ healthcare equity campaign
- Healing the Healers
- The (inevitable) digital transformation of Medical Affairs
- Novartis receives EC approval for Cosentyx in hidradenitis suppurativa
- Pfizer’s RSV vaccine approved by FDA for older adults
No results were found
PMHub
JPA Health
JPA Health is an award-winning public relations, marketing and advocacy firm known for sharing our clients’ commitment to making people...
Latest intelligence
- Healing the Healers
- Because if we do not heal the healers, who is going to heal us?...
- The (inevitable) digital transformation of Medical Affairs
- It’s not a question of ‘if,’ it’s a question of ‘when.’...
- Oncology eBook: Reducing the care gap in cancer prevention, diagnosis, and treatment
- Despite significant innovation in the oncology landscape, there is a growing care gap preventing patients accessing and benefiting from innovations in cancer treatment. In this new publication, our oncology experts...
